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Abstract
The 2011 NICE hypertension guideline (CG127) undertook a systematic review of the diagnostic accuracy of different blood
pressure (BP) assessment methods to confirm the diagnosis of hypertension. The guideline also undertook a cost–utility
analysis exploring the cost-effectiveness of the monitoring methods. A new systematic review was undertaken as part of the
2019 NICE hypertension guideline update (NG136). BP monitoring methods compared included Ambulatory BP, Clinic BP
and Home BP. Ambulatory BP was the reference standard. The economic model from the 2011 guideline was updated with
this new accuracy data. Home BP was more sensitive and specific than Clinic BP. Specificity improved more than sensitivity
since the 2011 review. A higher specificity translates into fewer people requiring unnecessary treatment. A key interest was
to compare Home BP and Ambulatory BP, and whether any improvement in Home BP accuracy would change the model
results. Ambulatory BP remained the most cost-effective option in all age and sex subgroups. In all subgroups, Ambulatory
BP was associated with lower costs than Clinic BP and Home BP. In all except one subgroup (females aged 40), Ambulatory
BP was dominant. However, Ambulatory BP remained the most cost-effective option in 40-year-old females as the
incremental cost-effectiveness ratio for Home BP versus Ambulatory BP was above the NICE £20,000 threshold. The new
systematic review showed that the accuracy of both Clinic BP and Home BP has increased. However, Ambulatory BP
remains the most cost-effective option to confirm a diagnosis of hypertension in all subgroups evaluated.
Introduction
The 2011 National Institute of Health and Care Excellence
(NICE) hypertension in adults guideline (CG127) [1]
undertook a systematic review and economic analysis, to
look at the diagnostic accuracy and cost-effectiveness of
different blood pressure (BP) monitoring methods for con-
firming a diagnosis of hypertension. Methods compared
were Ambulatory BP monitoring, Clinic BP monitoring and
Home BP monitoring.
The data used for the diagnostic accuracy of the com-
parisons in the 2011 guideline economic analysis were
based on a sensitivity analysis from the single systematic
review that informed the 2011 guideline clinical review [2].
The economic analysis found that Ambulatory BP was the
most cost-effective method of diagnosing hypertension [3].
As part of updating the Hypertension in adults guideline
(NG136) in 2019 [4], a new systematic review on the
diagnostic accuracy of BP monitoring methods for con-
firming a diagnosis of hypertension was performed. This
new data was added to the 2011 guideline economic model
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to assess whether the updated accuracy data would affect
the cost-effectiveness of different BP monitoring methods.
All other model inputs were left unchanged.
This manuscript details both the results of the systematic
review and results of the update to the economic model.
Methods
Diagnostic accuracy systematic review
The 2011 NICE hypertension guideline recommendations
were based on a systematic review that assessed the diag-
nostic accuracy of different BP measurements [2]. The
systematic review also undertook a sensitivity analysis
whereby the sensitivity and specificity of Clinic BP (com-
pared with Ambulatory BP) was based on a meta-analysis
that excluded studies with low-mean BP. In other words,
only studies with populations that had mean BPs close to or
above the diagnostic threshold were included as this was
more likely to represent a typical general practice screening
population.
The 2019 guideline update [4, 5] conducted a new
diagnostic accuracy review with the a priori inclusion and
exclusion criteria specified in Table 1. There were a number
of key differences between this review and that published in
2011, all of which aimed to improve the applicability
of results to UK routine clinical practice. Firstly, we
considered only studies published post-2000, as those before
this date commonly used mercury sphygmomanometers; a
method no longer used in routine clinical practice. Secondly,
individuals with chronic kidney disease, established cardi-
ovascular disease and type-2 diabetes were excluded for this
diagnostic accuracy review, as they were excluded from the
2019 guideline more broadly. Thirdly, the 2011 review
included studies performed in individuals who had a diag-
nosis of hypertension and, in some cases, were on anti-
hypertensive treatment. These studies were also excluded as
the accuracy of devices in the ‘suspected hypertension’
population might be different across a broader BP range or
for those already on antihypertensive treatment. A total of
five studies included in the 2011 review were therefore
excluded [6–10].
Full details of the systematic review, including full
inclusion criteria, search strategies and data synthesis, can
be found in the respective NICE guidelines [1, 4].
Cost-effectiveness analysis update
The data used for the diagnostic accuracy of the compar-
isons in the 2011 guideline economic analysis were based
on a sensitivity analysis from the single systematic review
that informed the 2011 guideline clinical review (see
Table 2) as the trials in the sensitivity analysis better
reflected a suspected hypertensive population. The 2019
review identified new diagnostic accuracy data for Clinic
Table 1 Differences in methods between the 2011 and 2019 NICE guideline systematic reviews.
2011 Review [1] 2011 Review (sensitivity analysis) [1] 2019 Review [4]
Population Adults Adults (excluding studies with low-mean
BP, i.e., excluding normotensive sample)
Adults with suspected hypertension
Target condition Hypertension Hypertension Hypertension
Index tests • Home BP
• Clinic BP
• Home BP
• Clinic BP
• Home BP without telemonitoring
• Home BP with telemonitoring
• Clinic BP
• Pharmacy monitoring
Reference standard Ambulatory BP (threshold
135/85 mmHg)
Ambulatory BP (threshold 135/85 mmHg) Ambulatory BP (threshold 135/85 mmHg)
Outcomes • Sensitivity
• Specificity
• Raw data to calculate 2 ×
2 data
• Sensitivity
• Specificity
• Raw data to calculate 2 × 2 data
• Sensitivity
• Specificity
• Raw data to calculate 2 × 2 data
• Studies where 2 × 2 data couldn’t be
derived were included but not meta-
analysed
Search strategy
(data limits)
1950 onwards 1950 onwards 2000 onwards
Other exclusion
criteria
• Studies where 2 × 2 data
couldn’t be derived
• Home with telemonitoring
• Studies where 2 × 2 data couldn’t be
derived
• Home with telemonitoring
– People with:
• Established (already diagnosed)
hypertension
• Type-2 diabetes
• Established cardiovascular disease
• Chronic kidney disease
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BP and Home BP, which could change the conclusions of
the previous modelling. The NICE guideline committee was
interested in the comparison of Home BP and Ambulatory
BP and whether this improvement in the accuracy of Home
BP would change the model results. As a result, a new
analysis was added to the 2011 guideline model as a minor
update, in which the only input that was changed was the
inclusion of the new accuracy data. All other inputs apart
from the diagnostic accuracy data remained the same, and
data on the methods of the previous model can be found in
Appendix J of the 2011 guideline [1].
A diagnostic meta-analysis was undertaken in Win-
BUGS software (version 14, University of Cambridge)
for the Clinic BP and Home BP data separately. In the
WinBUGS software, 60,000 paired estimates that form the
joint posterior distribution for sensitivity and specificity
were generated and extracted from the WinBUGS output
of the diagnostic meta-analysis. In the probabilistic sen-
sitivity analysis, a pair of sensitivity and specificity were
sampled at random, thus preserving the inverse correlation.
Five thousand simulations were run in the probabilistic
analysis.
Results
Diagnostic accuracy systematic review
The 2011 review included 20 studies investigating the
accuracy of different BP devices at various diagnostic
thresholds compared with the Ambulatory BP reference
standard. Meta-analysis was conducted with data from ten
studies for the most commonly reported diagnostic thresh-
olds (135/85 mmHg for Home BP, and 140/90 mmHg for
Clinic BP, compared with a reference standard threshold of
135/85 mmHg for Ambulatory BP) [1].
The 2019 review identified 13 studies that could be
included. Meta-analysis was conducted with data from
ten studies from the most commonly reported diagnostic
thresholds as above. The review stratified Home BP that
took place with and without telemonitoring, and also stra-
tified evidence for Clinic BP and Home BP based on the
diagnostic threshold used. This left a total of four studies
that were pooled for Home BP (without telemonitoring)
versus Ambulatory BP, and three studies that were pooled
for Clinic BP versus Ambulatory BP. A summary of the
results of each review is summarised in Table 2.
The sensitivities and specificities of the measures based
on the 2011 guideline (main analysis and sensitivity ana-
lysis), and the 2019 guideline, are summarised in Table 3
for comparison.
The 2019 review showed that the specificity of Home BP
increased compared with the previous model inputs by
around 20%, with the sensitivity also increasing slightly.
When compared with the results of the sensitivity analysis
from the 2011 meta-analysis for Clinic BP (after exclusion
of studies with normotensive people – see column labelled 2
in Table 3), the 2019 guideline data showed that the spe-
cificity of Clinic BP measurement also increased, but sen-
sitivity decreased slightly.
Cost-effectiveness analysis update
The new accuracy data and their distribution based on the
WinBUGS output can be seen in Table 4. This is different
to that in Table 3 because medians are used for clinical
meta-analysis of diagnostic accuracy data. This is because
diagnostic accuracy tends to have a skewed distribution,
whereas for economic analysis the means are more
appropriate.
Probabilistic results are summarised in Table 5 and
shown graphically in Fig. A in the Appendix. Using more
up to date diagnostic accuracy data confirms that a diag-
nosis of hypertension with Ambulatory BP following an
initial raised screening BP remained the most cost-effective
option in all age and sex subgroups.
Table 2 Differences in evidence
found between the 2011 and
2019 NICE guideline systematic
reviews.
2011 Review [1] 2011 Review
(sensitivity analysis) [1]
2019 Review [4]
Total included studies 20 3 13
Studies included in Home
BP meta-analysis (at
threshold of 135/85
mmHg)a
3 studies [6, 12, 13]
N= 561
Sensitivity analysis not conducted
(mean blood pressure of all
3 studies above normotensive
threshold)
4 studies [12, 14–16]
N= 963
Studies included in Clinic
BP meta-analysis (at
threshold of 140/90
mmHg)a
7 studies
[7–10, 13, 17, 18]
N= 3693
3 studies [7, 13, 17]
N= 809
3 studies [17, 19, 20]
N= 1250
aWhile both reviews searched for evidence at various diagnostic thresholds, most evidence was available for
the internationally accepted thresholds of 135/85 mmHg for Home BP and 140/90 mmHg Clinic BP; this
data was thus most appropriate for meta-analysis.
Options for the diagnosis of high blood pressure in primary care: a systematic review and economic model
Breakdowns of clinical events and costs, a summary of
the number of people initially misdiagnosed, and details of
how misdiagnosis changes over time, can also be found in
the Appendix along with the deterministic results.
In all subgroups, both Ambulatory BP and Home BP
were cost saving compared with Clinic BP, but Ambula-
tory BP was associated with lower costs than both Clinic
BP and Home BP. In all except one subgroup (females
aged 40), Ambulatory BP was associated with higher
QALYs (quality adjusted life years) than Clinic BP and
Home BP. Ambulatory BP was therefore dominant (both
cheaper and more effective) in all except one subgroup.
However, Ambulatory BP was still the most cost-effective
option in 40-year-old females because the additional
benefit of Home BP did not justify the additional cost
(as can be seen from the incremental cost-effectiveness
ratio on the top left cost-effectiveness plane in Fig. A in
the Appendix) as the cost-effectiveness ratio for Home BP
compared with Ambulatory BP was above the £20,000
threshold.
In the 2011 guideline model, for some of the younger
male and female groups, the incremental QALYs of both
Home BP and Ambulatory BP versus Clinic BP were
negative, meaning that Home BP and Ambulatory BP
measurement provided fewer QALYs than Clinic BP, but
they were also cheaper.
Discussion
Diagnostic accuracy systematic review
A new systematic review on the diagnostic accuracy of
methods to diagnose hypertension was undertaken as part of
the 2019 NICE guideline, and the economic model of cost-
effectiveness has been updated. In this updated analysis,
overall the new systematic review showed that there has
been an increase in the specificity of both Clinic BP and
Home BP when compared with Ambulatory BP as a
reference standard. This may have occurred for a number of
reasons:
(1) The studies themselves may be more rigorous in their
methods.
(2) The 2019 systematic review may be more rigorous than
the 2011 systematic review, for example by removing
pre-2000 studies that may have been less accurate, and
only including a population that replicates the popula-
tion seen in clinical practice.
(3) It is also possible that differences could have occurred
by chance, as it is difficult to replicate the true
‘suspected hypertension’ population in a study and the
number of participants were overall fairly small.
Table 4 New diagnostic accuracy data for model.
Input Data Probability distribution
Sensitivity
Clinic BP 78% (95% CI: 46, 95)
Home BP 88% (95% CI: 67, 98)
Ambulatory BP 100% Fixed
Specificity
Clinic BP 72% (95% CI: 20, 98)
Home BP 81% (95% CI: 52, 96)
Ambulatory BP 100% Fixed
Table 3 Comparison of
diagnostic accuracy data across
2011 and 2019 NICE guidelines
systematic reviews.
(1) 2011 Guideline clinical
reviewa
(2) 2011 Guideline clinical
review (sensitivity analysis)b
(3) 2019 Guideline clinical
reviewc
Data 95% Confidence
interval
Data 95% Confidence
interval
Data 95% Confidence
interval
Sensitivity
Clinic BP 75% 61, 84 86% 81, 89 81% 47, 95
Home BP 86% 78, 91 – – 90% 68, 98
Specificity
Clinic BP 75% 48, 90 46% 33, 59 76% 20, 98
Home BP 62% 48, 75 – – 84% 53, 96
Ambulatory BP is assumed to have a sensitivity and specificity of 100% as it is the reference standard.
aThis is based on the main meta-analysis from Hodgkinson et al. [2].
bThis is based on the sensitivity analysis from Hodgkinson et al. [2] that excluded studies with a
normotensive population. This only affected the Clinic BP data.
cThis data is based on medians because there was a skewed distribution in the accuracy data. Pooling means
is only appropriate when data is normally distributed, as reported in section 9.4.5.3 of the Cochrane
handbook [11]. The mean diagnostic accuracy data was used in the systematic review included as part of the
2011 guideline.
M. Constanti et al.
(4) The country setting of the studies may have an
influence and could possibly impact the accuracy data
because different countries may have different practices
in how to measure and diagnose hypertension.
(5) In addition, the methods used in terms of whether mean
or median accuracies are reported are different in the
2011 review (reported means) and in the 2019 review
(reported medians as suggested by the Cochrane
handbook because the data had a skewed distribution)
[11]. Medians are likely to be higher than means
because diagnostic accuracy data tend to be positively
skewed (have a longer right tail towards higher values).
This can be seen in the final column of Table 3, where
there were also wider confidence intervals from the
2019 review than from the 2011 review.
Cost-effectiveness analysis update
Given more modern accuracy data, the update to the model
shows that Ambulatory BP remains the most cost-effective
method for confirming a diagnosis of hypertension for all
age and sex subgroups. It is also dominant in more sub-
groups than previously. Ambulatory BP remains the most
cost-effective method of diagnosis because the additional
benefit justifies the cost.
In the 2011 guideline model, the lower QALYs of Home
BP and Ambulatory BP compared with Clinic BP in some
subgroups could be explained because misdiagnosing
people with a measurement method that had a lower spe-
cificity (Clinic BP) led to an unexpected advantage of some
people getting treatment, and therefore cardiovascular dis-
ease risk reduction, sooner, before they became hyperten-
sive and potentially untreated in the period before they next
have a BP check-up. This effect works to counteract some
of the benefits of accurately diagnosing people with
hypertension with more accurate methods, such as Ambu-
latory BP. The effect is more prominent in younger people
because they have a lower prevalence of hypertension and
therefore specificity plays a greater role in the results than
sensitivity (see previous model write-up in the Appendix J
of the previous guideline for more detail) [1]. However, in
this new analysis, as the specificity of Clinic BP has
increased, this anomalous effect is less prominent, and
Ambulatory BP is dominant in more subgroups than it was
previously, predominantly because the new accuracy data is
showing higher specificities for Clinic BP and Home BP.
The initial numbers of misdiagnoses per 1000 people
with suspected hypertension are shown in Table D in the
Appendix. False positives and negatives over time can be
seen in Figs. B, C in the Appendix. As the specificity of
Clinic BP and Home BP increases, the number of false
positives falls compared with the base-case analysis of theTa
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previous model. The sensitivity of Clinic BP falls in the
new data used, which leads to a slight increase in the
number of false negatives (those who are normotensive but
have been labelled as being hypertensive and will be sub-
jected to treatment). The number of false positives for
Ambulatory BP also decreases, and it is likely that those
who fail Ambulatory BP are diagnosed with Clinic BP. As
the specificity of Clinic BP has improved, this leads to
fewer false positives.
Clinical conclusions
Home BP remains the best alternative method for diag-
nosing hypertension where Ambulatory BP is not available,
however Ambulatory BP is the most cost-effective method,
and likely to lead to cost savings when implemented
(compared with Clinic BP and Home BP). Savings follow
from correctly identifying those people who require BP
treatment, and also identifying those who should not be
treated.
Summary
What is known about this topic
● Ambulatory BP is the most accurate method to diagnose
hypertension, and is generally used as the reference
standard when investigating the accuracy of Home BP
and Clinic BP.
● Previous systematic reviews have shown that Home BP
and Clinic BP have lower sensitivity and specificity than
Ambulatory BP in the diagnosis of hypertension.
● Despite Ambulatory BP being the most expensive
method, its use is cost-effective due to its diagnostic
accuracy.
What this study adds
● A new systematic review of diagnostic accuracy of
different methods of measuring BP has been undertaken
as part of updating the NICE hypertension guideline.
● Compared with the 2011 hypertension guideline,
sensitivity and specificity increased for Home BP, and
specificity increased for Clinic BP.
● Ambulatory BP remains the most cost-effective method
of diagnosing hypertension in all age and sex subgroups.
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